-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: PRS-342...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Solid Tumor Drug Details: PRS-342 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Gastric Cancer Drug Details: PRS-343 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bersiporocin in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bersiporocin in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bersiporocin in Idiopathic Pulmonary Fibrosis Drug Details: Bersiporocin (DWN-12088, DWJ-209) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Refractory Acute Myeloid Leukemia Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Relapsed Acute Myeloid Leukemia Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Triple-Negative Breast Cancer (TNBC) Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRS-344 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRS-344 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRS-344 in Solid Tumor Drug Details: PRS-344 is under development for...